Synaptic degeneration in Alzheimer disease
Alzheimer disease (AD) is characterized by progressive cognitive decline in older
individuals accompanied by the presence of two pathological protein aggregates—amyloid …
individuals accompanied by the presence of two pathological protein aggregates—amyloid …
The amyloid cascade hypothesis: an updated critical review
Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …
disease have created excitement and have been heralded as corroboration of the amyloid …
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of …
E McDade, JL Cummings, S Dhadda… - Alzheimer's research & …, 2022 - Springer
Abstract Background Lecanemab, a humanized IgG1 monoclonal antibody that targets
soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid …
soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid …
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
CJ Swanson, Y Zhang, S Dhadda, J Wang… - Alzheimer's research & …, 2021 - Springer
Abstract Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially
targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and …
targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and …
The amyloid-β oligomer hypothesis: beginning of the third decade
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …
[HTML][HTML] Is Alzheimer's disease a type 3 diabetes? A critical appraisal
R Kandimalla, V Thirumala, PH Reddy - Biochimica et Biophysica Acta …, 2017 - Elsevier
Recently researchers proposed the term 'Type-3-Diabetes' for Alzheimer's disease (ad)
because of the shared molecular and cellular features among Type-1-Diabetes, Type-2 …
because of the shared molecular and cellular features among Type-1-Diabetes, Type-2 …
Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons
R Rajmohan, PH Reddy - Journal of Alzheimer's Disease, 2017 - content.iospress.com
Amyloid-beta (Aß) and hyperphosphorylated tau are hallmark lesions of Alzheimer's disease
(AD). However, the loss of synapses and dysfunctions of neurotransmission are more …
(AD). However, the loss of synapses and dysfunctions of neurotransmission are more …
The intersection of amyloid beta and tau at synapses in Alzheimer's disease
TL Spires-Jones, BT Hyman - Neuron, 2014 - cell.com
The collapse of neural networks important for memory and cognition, including death of
neurons and degeneration of synapses, causes the debilitating dementia associated with …
neurons and degeneration of synapses, causes the debilitating dementia associated with …
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis
Protein aggregation is common to dozens of diseases including prionoses, diabetes,
Parkinson's and Alzheimer's. Over the past 15 years, there has been a paradigm shift in …
Parkinson's and Alzheimer's. Over the past 15 years, there has been a paradigm shift in …
Identification of Alzheimer's disease using a convolutional neural network model based on T1-weighted magnetic resonance imaging
The classification of Alzheimer's disease (AD) using deep learning methods has shown
promising results, but successful application in clinical settings requires a combination of …
promising results, but successful application in clinical settings requires a combination of …